Oncolytics Biotech Inc
ONCY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001129928
No open-market purchases or sales by Oncolytics Biotech Inc insiders were filed in the last 90 days; 76 institutions reported holding it in 13F filings for Q2 2026, worth $3.77M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Oncolytics Biotech Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Oncolytics Biotech Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Glover Steve C | Director | – | Jun 3, 2026 | 1 |
| Rigby Jonathan | Director | – | Jun 3, 2026 | 1 |
| Andrews Patricia S | Director | 78,128 | Jun 3, 2026 | 2 |
| Pisano Wayne | Director | 492,414 | Jun 3, 2026 | 2 |
| Parsons James T. | Director | 41,849 | Jun 3, 2026 | 2 |
| Seizinger Bernd R. | Director | 566,991 | Jun 3, 2026 | 3 |
| Aromando Andrew | Chief Business Officer | 55,100 | Jun 3, 2026 | 2 |
| Holtham Angela | Director | – | Jun 3, 2026 | 1 |
| Heineman Thomas Charles | Chief Medical Officer | 282,818 | Jun 3, 2026 | 2 |
| Brown Deborah Margaret | Director | 109,851 | Jun 3, 2026 | 2 |
| Kelly Jared | Chief Executive Officer | 114,050 | Jun 3, 2026 | 3 |
| Look Kirk | Chief Financial Officer | 287,515 | Jun 3, 2026 | 2 |
| Hagerman Allison | Chief Technology Officer | 115,059 | Jun 3, 2026 | 2 |
| McAdory John Bearden | Chief Operating Officer | – | Jun 3, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 13, 2026 (view filing) | Mar 11 | 2 days | Parsons James T.Director | PPurchase | +10.0K | $1.03 | +$10.3K | +31.4%41.8K after | |
| Mar 13, 2026 (view filing) | Mar 12 | 1 day | Kelly JaredChief Executive Officer | PPurchase | +5.05K | $0.96 | +$4.85K | +4.6%114.0K after | |
| Feb 13, 2026 (view filing) | Feb 11-12 | 2 days | Seizinger Bernd R.Director | PPurchase | +100.0K | $0.838 | +$83.8K | +21.4%567.0K after | 2 lots |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Pisano WayneDirector | PPurchase | +30.0K | $0.84 | +$25.2K | +6.5%492.4K after | |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Look KirkChief Financial Officer | PPurchase | +12.0K | $0.84 | +$10.1K | +4.4%287.5K after | |
| Feb 13, 2026 (view filing) | Feb 11-12 | 2 days | Kelly JaredChief Executive Officer | PPurchase | +35.1K | $0.84 | +$29.5K | +47.5%109.0K after | 2 lots |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Heineman Thomas CharlesChief Medical Officer | PPurchase | +12.1K | $0.83 | +$10.1K | +4.5%282.8K after | |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Hagerman AllisonVP, Product Development | PPurchase | +10.0K | $0.83 | +$8.30K | +9.5%115.1K after | |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Brown Deborah MargaretDirector | PPurchase | +25.0K | $0.85 | +$21.3K | +29.5%109.9K after | |
| Feb 13, 2026 (view filing) | Feb 11 | 2 days | Aromando AndrewChief Business Officer | PPurchase | +29.6K | $0.86 | +$25.5K | +116.1%55.1K after | |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Andrews Patricia SDirector | PPurchase | +35.4K | $0.86 | +$30.4K | +82.8%78.1K after | |
| Jan 20, 2026 (view filing) | Jan 16 | 4 days | Seizinger Bernd R.Director | PPurchase | +100.0K | $1.04 | +$104.0K | +27.2%467.0K after |